Aim: Macular pigment density and microvascular density on optical coherence tomography angiography (OCTA) were measured in a cohort of type 1 diabetes mellitus (T1DM) patients with retinopathy in the attempt to shed light on the pathophysiology of this condition. Methods: Eighty-two consecutive eyes of 59 patients with diabetic retinopathy examined at the Eye Clinic of the University of Naples Federico II from November 2016 to April 2017 were enrolled in this prospective study. Eighty normal eyes of 40 age-matched subjects without diabetes mellitus, without a history of glaucoma or evidence of intraocular surgery, and without retinal pathologic features constituted the control group. All patients and controls underwent a complete ophthalmic examination, best corrected visual acuity evaluation according to the ETDRS visual logMAR scale, measurement of intraocular pressure, OCTA, and evaluation of macular pigment. Results: There were no significant age differences between patients and controls. Both macular pigment measurements and vessel density measured by OCTA were significantly lower in patients than in controls. A moderate correlation was found between vessel density in all ETDRS sectors and macular pigment parameters. Conclusions: There was a reduction in macular pigment and in OCTA vessel density in T1DM patients with retinopathy, which may have prognostic value in determining disease progression.

1.
Klein R: The epidemiology of diabetic retinopathy: findings from the Wisconsin epidemiologic study of diabetic retinopathy. Int Ophthalmol Clin 1987; 27: 230–238.
2.
Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E: Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 2000; 78: 374–385.
3.
Antonetti D, Klein R, Gardner TW: Diabetic retinopathy. N Engl J Med 2012; 366: 1227–1239.
4.
Durham JT, Herman IM: Microvascular modifications in diabetic retinopathy. Curr Diab Rep 2011; 11: 253–264.
5.
Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A: Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. Invest Ophthalmol Vis Sci 2010; 51: 6729–6734.
6.
Agrawal R, Xin W, Keane PA, Chhablani J, Agarwal A: Optical coherence tomography angiography: a non-invasive tool to image end-arterial system. Expert Rev Med Devices 2016; 13: 519–521.
7.
Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH: Quantifying microvascular density and morphology in diabet ic retinopathy using spectral-domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci 2016; 57: 362–370.
8.
Linsenmeier RA, Braun RD: Oxygen distribution and consumption in the cat retina during normoxia and hypoxemia. J Gen Physiol 1992; 99: 177–197.
9.
Kowluru RA, Kowluru A, Mishra M, Kumar B: Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res 2015; 48: 40–61.
10.
Al-Sheikh M, Akil H, Pfau M, Sadda S: Swept-source OCT angiography imaging of the foveal avascular zone and macular capillary network density in diabetic retinopathy. Invest Ophthalmol Vis Sci 2016; 57: 3907–3913.
11.
Yildirim Z, Ucgun NI, Yildirim F: The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. Clinics (Sao Paulo) 2011; 66: 743–746.
12.
She CY, Gu H, Xu J, Yang XF, Ren XT, Liu NP: Association of macular pigment optical density with early stage of non-proliferative diabetic retinopathy in Chinese patients with type 2 diabetes mellitus. Int J Ophthalmol 2016; 9: 1433–1438.
13.
Loane E, Nolan JM, Beatty S: The respective relationships between lipoprotein profile, macular pigment optical density, and serum concentrations of lutein and zeaxanthin. Invest Ophthalmol Vis Sci 2010; 51: 5897–5905.
14.
Lima VC, Rosen RB, Maia M, Prata TS, Dorairaj S, Farah ME, Sallum J: Macular pigment optical density measured by dual-wavelength autofluorescence imaging in diabetic and nondiabetic patients: a comparative study. Invest Ophthalmol Vis Sci 2010; 51: 5840–5845.
15.
Cheung N, Mitchell P, Wong TY: Diabetic retinopathy. Lancet 2010; 376: 124–136.
16.
Trieschmann M, van Kuijk FJ, Alexander R, Hermans P, Luthert P, Bird AC, Pauleikhoff D: Macular pigment in the human retina: histological evaluation of localization and distribution. Eye (Lond) 2008; 22: 132–137.
17.
Howells O, Eperjesi F, Barlett H: Measuring macular pigment optical density in vivo: a review of techniques. Graefes Arch Clin Exp Ophthalmol 2011; 249: 315–347.
18.
Bernstein PS, Delori FC, Richer S, van Kuijik FJ, Wenzel AJ: The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. Vision Res 2010; 50: 716–728.
19.
Kaya S, Weigert G, Pemp B, Sacu S, Werkmeister RM, Dragostinoff N: Comparison of mac-ular pigment in patients with age-related macular degeneration and healthy control sub jects – a study using spectral fundus reflectance. Acta Ophthalmol 2012; 90:e399–e403.
20.
Carnevali A, Sacconi R, Corbelli E, Tomasso L, Querques L, Zerbini G, Scorcia V, Bandello F, Querques G: Optical coherence tomography angiography analysis of retinal vascular plexuses and choriocapillaris in patients with type 1 diabetes without diabetic retinopathy. Acta Diabetol 2017; 54: 695–702.
21.
Rabiolo A, Carnevali A, Bandello F, Querques G: Optical coherence tomography angiography: evolution of revolution? Expert Rev Ophthalmol 2016; 11: 243–245.
22.
Frank RN: Diabetic retinopathy. N Engl J Med 2004; 350: 48–58.
23.
Hammes HP, Feng Y, Pfister F, Brownlee M: Diabetic retinopathy: targeting vasoregression. Diabetes 2011; 60: 9–16.
24.
Agemy SA, Scripsema NK, Shah CM, Chui T, Garcia PM, Lee JG, Gentile RC, Hsiao YS, Zhou Q, Ko T, Rosen RB: Retinal vascular perfusion density mapping using optical coherence tomography angiography in normal and diabetic retinopathy patients. Retina 2015; 35: 2353–2363.
25.
Simonett JM, Scarinci F, Picconi F, Giorno P, De Geronimo D, Di Renzo A, Varano M, Frontoni S, Parravano M: Early microvascular retinal changes in optical coherence tomography angiography in patients with type 1 diabetes mellitus. Acta Ophthalmol 2017; 95: 751–755.
26.
Couturier A, Mané V, Bonnin S, Erginay A, Massin P, Gaudric A, Tadayoni R: Capillary plexus anomalies in diabetic retinopathy on optical coherence tomography angiography. Retina 2015; 35: 2384–2391.
27.
Mané V, Dupas B, Gaudric A, Bonnin S, Pedinielli A, Bousquet E, Erginay A, Tadayoni R, Couturier A: Correlation between cystoid spaces in chronic diabetic macular edema and capillary nonperfusion detected by optical coherence tomography angiography. Retina 2016; 36(suppl 1):S102–S110.
28.
Sambhav K, Grover S, Chalam KV: Extreme diurnal variation of central macular thickness in diabetic macular edema. Retin Cases Brief Rep 2017, Epub ahead of print.
29.
Van Reyk BM, Gillies MC, Davies MJ: Oxidative stress and diabetes. Redox Rep 2003; 8: 187–192.
30.
Koworlu RA, Chan PS: Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007; 2007: 43603.
31.
Nakahara T, Hoshino M, Hoshino S, Mori A, Sakamoto K, Ishii K: Structural and functional changes in retinal vasculature induced by retinal ischemia-reperfusion in rats. Exp Eye Res 2015; 135: 134–145.
32.
Dmitriev AV, Henderson D, Linsenmeier RA: Development of diabetes-induced acidosis in the rat retina. Exp Eye Res 2016; 149: 16–25.
33.
Sommerburg OG, Siems WG, Hurst JS, Lewis JW, Kliger DS, van Kuijk FJ: Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res 1999; 19: 491–495.
34.
Beatty S, Koh H, Phil M, Henson D, Boulton M: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115–134.
35.
Nolan JM, Stack J, Eamonn OC, Beatty S: The relationship between macular pigment optical density and its constituent carotenoids in diet and serum. Invest Ophthalmol Vis Sci 2007; 48: 571–582.
36.
Bone RA, Landrum JT: Distribution of macular pigments components, zeaxanthin and lutein, in human retina. Methods Enzymol 1992; 213: 360–366.
37.
Khachik FB, Bernstein PS, Garland DL: Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38: 1802–1811.
38.
Forte R, Panzella L, Cesarano I, Cennamo G, Eidenberger T, Napolitano A: Epilutein for early-stage age-related macular degeneration: a randomized and prospective study. Ophthalmic Res 2017; 58: 231–241.
39.
Davies NP, Morland AB: Color matching in diabetes: optical density of the crystalline lens and macular pigments. Invest Ophthalmol Vis Sci 2002; 43: 281–289.
40.
Hammond BJ, Fuld K, Curran-Celentano J: Macular pigment density in monozygotic twins. Invest Ophthalmol Vis Sci 1995; 36: 2531–2541.
41.
Granado F, Olmedilla B, Gil-Martínez E, Blanco I, Millan I, Rojas-Hidalgo E: Carotenoids, retinol and tocopherols in patients with insulin-dependent diabetes mellitus and their immediate relatives. Clin Sci (Lond) 1998; 94: 189–195.
42.
Ford E, Will J, Bowman B, Narayan K: Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Study. Am J Epidemiol 1999; 149: 168–176.
43.
Beatty S, Boulton M, Henson D, Koh HH, Murray IJ: Macular pigment and age related macular degeneration. Br J Ophthalmol 1999; 83: 867–877.
44.
Engerman RL, Kern TS: Hyperglycemia as a cause of diabetic retinopathy. Metabolism 1986; 35: 20–23.
45.
Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1–9.
46.
Haskins K, Bradley B, Powers K, Fadok V, Flores S, Ling X, Pugazhenthi S, Reusch J, Kench J: Oxidative stress in type 1 diabetes. Ann NY Acad Sci 2003; 1005: 43–54.
47.
Scanlon G, Connell P, Ratzlaff M, Foerg B, McCartney D, Murphy A, O’Connor K, Loughman J: Macular pigment optical density is lower in type 2 diabetes, compared with type 1 diabetes and normal controls. Retina 2015; 35: 1808–1816.
48.
Applegate RA, Bradley A, van Heuven WA, Lee BL, Garcia CA: Entoptic evaluation of diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 783–791.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.